Hikma Pharmaceuticals has named ViiV Healthcare finance chief Rebecca Hall as its next chief financial officer, adding fresh Leadership as the generic drugmaker sticks to its full-year guidance.
Hikma Pharmaceuticals (LSE:HIK) has filled a key boardroom role, announcing on 24 September that Rebecca Hall will join as chief financial officer and executive director. The appointment comes at a time when investors in the FTSE 250 pharmaceuticals group are focused on Margin trends in its core US injectables Business and on the delivery of an ongoing share buyback.
A seasoned pharmaceutical finance executive
Ms Hall is currently senior vice president and CFO of ViiV Healthcare, the HIV specialist majority-owned by GSK, where she oversees finance, Supply chain and business development. She spent 14 years at GSK in commercial, strategic and Supply Chain Finance roles across the UK, Europe and emerging markets, including a period as chief of staff to the group CFO. She joined ViiV in 2018, later moving to the US to lead its North American finance function, before becoming CFO in 2024.
She is expected to join Hikma during the first quarter of 2027, with the exact date to be confirmed. Khalid Nabilsi will step down from the board on 31 December 2026 but will remain on the executive committee as deputy chief executive for North America and Europe, while Areb Kurdi continues as acting CFO in the interim. Chief executive Said Darwazah described Ms Hall as an accomplished pharmaceutical leader. The company also announced an R&D investor spotlight series in late September, designed to give the market greater insight into its development pipeline.
Steady first half, guidance maintained
The leadership change follows a first half that management described as in line with expectations. In the six months to June, Revenue rose 4% to $1,728m and core operating profit increased 9% to $405m, giving a core Operating Margin of 23.4%. Core Basic Earnings Per Share climbed to 128 cents, and the Interim Dividend was raised 6% to 38 cents.
Performance varied across the group. Branded, which serves the Middle East and North Africa, was the standout, with revenue up 15% and core operating profit up 23%. Hikma Rx revenue edged down 1%, although profitability improved. Injectables revenue was flat at $685m, and core operating profit in the division fell 8% as the margin narrowed to 27.6% from 30.0%.
Hikma reiterated its 2026 guidance for group revenue growth of 2% to 4% and core operating profit of $720m to $770m at constant currency. It expects Branded growth at the top of its previous 6% to 8% range and Injectables growth in the low single digits, with a core margin of 27% to 28%. By early August the company had repurchased $227m of shares under its $250m buyback programme.
Sector backdrop
The generic and injectable drug market in the United States remains competitive, with pricing pressure and supply dynamics shaping profitability. US trade policy, including the potential for tariffs on imported pharmaceuticals, has also been a recurring theme for sector investors, and Hikma's sizeable US Manufacturing footprint is often cited as a relative strength in that debate.
For FTSE 250 investors, the coming months bring several points to monitor: injectables margin recovery, the contribution from new launches and pipeline Assets highlighted in the R&D sessions, and completion of the buyback. The CFO transition is expected to be orderly, with continuity provided by existing executives during the handover.






Please wait processing your request...